Physician profile
Dorrie E Chang
NPI 1114952470
$888.99
in general payments reported to CMS, 2019-2025
13 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2023: $342 · 2024: $76.72 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $235.13 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $120.08 | 2025 | Auvelity |
| Novo Nordisk INC | $117.30 | 2019 | |
| Nestle Healthcare Nutrition INC. | $88.22 | 2023 | |
| Aimmune Therapeutics, INC. | $86.52 | 2024-2025 | Vowst |
| Qol Medical, LLC | $60.39 | 2025 | Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.31 | 2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $28.77 | 2023 | Entyvio |
| Alnylam Pharmaceuticals INC. | $28.27 | 2023 | Givlaari |
| Ardelyx, INC. | $25.45 | 2023 | Ibsrela |
| Lilly USA, LLC | $25.31 | 2025 | Zepbound, Mounjaro |
| Janssen Biotech, INC. | $18.86 | 2023 | Stelara |
| Ani Pharmaceuticals, INC. | $18.38 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorrie Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.